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Achilleas Chatziioannou, MD, Kostas Palialexis, MD
Renal artery stenosis (RAS), hypertension and renal insufficiency (RI) are each 
frequently present especially in the elderly population. RAS is often present without 
any clinical signs or symptoms and even when hypertension or renal insufficiency are 
also present, they may be coincidentally rather than causally related. However, when 
RAS is hemodynamically or physiologically significant, it is one of the few potentially 
reversible causes of RI and hypertension.
The challenge for physicians is to identify patients with RAS who would benefit 
from renal revascularization, whether by interventional techniques or open surgery. 
RAS is often clinically silent, at least until it becomes hemodynamically significant 
when it can produce renal vascular hypertension (RVH) or RI.
Selection for intervention must consider and integrate the clinical, anatomic 
and physiologic status of the patient and the risk and benefit of alternative medical 
and invasive therapies must be compared to each other and to the natural history 
of the disease. Prior to renal artery intervention the physiological significance of a 
stenosis should be confirmed by demonstrating a hemodynamically significant 10% 
peak systolic trans-stenotic pressure gradient, in addition to appropriate clinical and 
anatomic indications. RVH, especially if due to unilateral disease, is usually easily 
and well controlled by modern anti-hypertensive medications, especially angiotensin 
converting enzyme inhibitors (ACEI). Ischemic nephropathy, one of the few revers-
ible causes of RI in adults is the most appropriate indication for intervention in renal 
artery occlusive disease.
All of these hemodynamic and humoral mechanisms contribute to major adverse 
cardiovascular events (MACE) such as death, dialysis, myocardial infarction and 
stroke. The terms RAS and atheromatous renal artery stenosis (ARAS), physiologically 
or hemodynamically significant RAS and ARAS and RVH are often used interchange-
ably.  Others recommend intervention (stenting) for any RAS even if the stenosis is 
physiologically and clinically not significant, though Zeller recently acknowledged 
that antistatin therapy may be an important alternative. It has even been suggested by 
some in lectures, though not in writing, that any, even physiologically not significant 
RAS can produce adverse cardiovascular effects by mysterious hemodynamic and 
humoral effects. There is no evidence to support this concept. 
Some advocate prophylactic intervention for asymptomatic and hemodynamically 
non significant RAS lesions based on the following: 
 1. ARAS is a progressive disease and “progressive worsening of ARAS stenosis 
occurs despite medical therapy that effectively controls blood pressure”
 2. Therefore, unless prophylacticaly and aggressively treated by mechanical (stent-
ing) intervention, ARAS will progress to cause severe hypertension and renal 
insufficiency with their attendant MACE at which point the disease is no longer 
reversible or controllable by interventional treatment.
 3. Early prophylactic intervention in a less diseased renal artery and aorta is techni-
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cally easier and less likely to result in complications.
These arguments are at first persuasive, but are based on 
inadequate or incorrect assumptions or information much of 
which is no longer current.
Most of the studies on the progression of renal artery sten-
osis overestimate the progression of atheromatous renal artery 
disease; they predate the widespread aggressive use of statins, 
exquisite control of RVH by drugs specifically targeting renin 
dependent hypertension, the aggressive control of glucose 
and efforts at lifestyle modifications affecting smoking, diet, 
exercise and weight control especially in high risk populations. 
In fact, several large studies have recently confirmed the arrest 
of progression and in some cases regression of atheromatous 
plaque in the coronary and carotid arteries by aggressive 
treatment with statins; there is no reason to postulate that 
these beneficial effects do not apply to the renal circulation. 
It seems reasonable then to treat all patients with such asymp-
tomatic and hemodynamically non significant ARAS lesions 
with aggressive statin therapy, aspirin and other appropriate 
medications and lifestyle modifications. This would likely 
produce all the potential benefits of aggressive interventional 
stent treatment whose very long term durability and fate is 
unknown and without any of its known major risks such as 
cholesterol embolization and without the 15-20 % restenosis 
all of which can occur even in “low risk” patients.
Statins and risk reduction are the new paradigm for the 
treatment of all atheroma, especially when clinically and 
hemodynamically not significant, but also for clinically and 
physiologically significant stenoses following interventional 
treatment. 
In summary, appropriately selected patients with ARAS 
and RI benefit from interventional therapy, while those with 
clinically and hemodynamically non significant stenoses 
should be treated by aggressive medical therapy including 
statins and life style modifications.
A N G I O P L A s t Y  I N  N O N - 
A t H E r O m A t O U s  L E s I O N s
f I b r O m U s c U L A r  D Y s P L A s I A  ( f m D )
Generally, percutaneous transluminal angioplasty is con-
sidered to be a method of choice for FMD treatment. Stents 
are usually not used as a primary measure, but they are helpful 
in renal angioplasty suboptimal result or failure.
The main clinical symptoms of FMD are hypertension and 
ischemic nephropathy, but this is less frequent. In technically 
successful cases, the positive clinical response occurs in over 
0% of cases. Stent implantation is used rarely, mainly as a 
bail-out procedure in angioplasty complication or failure.
A r t E r I t I s
Stenoses usually affecting the longer segments of main 
renal artery respond favorably to angioplasty, and the dilation 
should not be performed during active period of the disease. 
Stents are not used very frequently.
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